251 completed, 60 terminated, 11 recruiting, 11 withdrawn. 159 Phase 2, 148 Phase 1, 32 Not applicable, 26 Phase 3, 3 Phase 4.
Follow Blast Crisis: new trials by email Literature Review of Blast Crisis trials Research Report on Blast Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-07-06 |
| Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg - Myeloproliferative Neoplasm | Phase 1 | Terminated | Joseph Jurcic | 2 | 2022-01-28 | 2024-04-23 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Bosutinib - Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia | Phase 1 / Phase 2 | Active not recruiting | Children's Oncology Group | 60 | 2020-07-06 | 2026-10-01 |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia Decitabine, Ponatinib, Venetoclax - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2020-05-17 | 2026-06-05 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Ponatinib - Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Incyte Biosciences International Sàrl | 70 | 2020-01-29 | 2026-10-09 |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab - Leukemia, Myeloid, Chronic, Myeloid Leukemia | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 242 | 2020-01-09 | 2025-11-05 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 72 | 2019-01-31 | 2026-09-18 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy Edetate Calcium Disodium, Multivitamin, Succimer - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 58 | 2018-10-11 | 2026-09-18 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Cladribine, Cytarabine, Dexrazoxane Hydrochloride - Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2018-09-19 | 2026-05-22 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL | Terminated | Ariad Pharmaceuticals | 3 | 2018-03-02 | 2024-04-04 | |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 22 | 2018-02-08 | 2026-08-19 |
| CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia | Completed | Incyte Biosciences UK | 427 | 2017-12-18 | 2021-08-16 |
Showing 20 of 356. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (277) · Leukemia, Myeloid, Acute (263) · Leukemia, Myeloid, Accelerated Phase (244) · Leukemia (211) · Leukemia, Myeloid, Chronic-Phase (205) · Leukemia, Lymphocytic, Chronic, B-Cell (191) · Burkitt Lymphoma (178) · Lymphoma, Large B-Cell, Diffuse (172) · Lymphoma, Mantle-Cell (171) · Lymphoma, Non-Hodgkin (171) · Lymphoma, Follicular (170) · Myelodysplastic Syndromes (168) · Lymphoma, B-Cell, Marginal Zone (163) · Lymphoma, Large-Cell, Immunoblastic (163)
Bone Marrow Diseases (356) · Carcinogenesis (356) · Cell Transformation, Neoplastic (356) · Chronic Disease (356) · Disease Attributes (356) · Hemic and Lymphatic Diseases (356) · Neoplasms by Histologic Type (356) · Neoplastic Processes (356) · Pathologic Processes (356) · Pathological Conditions, Signs and Symptoms (356) · Hematologic Diseases (353) · Leukemia, Myeloid (351) · Neoplasms (321) · Immune System Diseases (289) · Immunoproliferative Disorders (287)
Cyclophosphamide (64) · Peripheral Blood Stem Cell Transplantation (58) · fludarabine phosphate (55) · Busulfan (44) · Tacrolimus (39) · Methotrexate (38) · Cytarabine (37) · Filgrastim (34) · Cyclosporine (33) · Mycophenolic Acid (33) · Antilymphocyte Serum (32) · Whole-Body Irradiation (28) · Radiotherapy (25) · Etoposide (22) · Imatinib Mesylate (22)
Fred Hutchinson Cancer Center (41) · National Cancer Institute (NCI) (40) · M.D. Anderson Cancer Center (30) · Memorial Sloan Kettering Cancer Center (18) · Case Comprehensive Cancer Center (14) · City of Hope Medical Center (12) · Masonic Cancer Center, University of Minnesota (8) · Roswell Park Cancer Institute (8) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · Jonsson Comprehensive Cancer Center (7) · OHSU Knight Cancer Institute (7) · Barbara Ann Karmanos Cancer Institute (6) · Novartis Pharmaceuticals (6) · University of Maryland, Baltimore (6) · Vanderbilt-Ingram Cancer Center (6)
United States (318) · Canada (21) · Italy (13) · France (12) · Germany (12) · Belgium (7) · South Korea (7) · Switzerland (7) · United Kingdom (7) · Turkey (Türkiye) (5) · Israel (4) · Netherlands (4) · Slovakia (4) · Spain (4) · Australia (3)
Judith E. Karp, MD (5) · Kyoo H. Lee, MD (5) · Brenda W. Cooper, MD (4) · Jorge Cortes (4) · Jorge Cortes, MD (4) · Ann E. Woolfrey, MD (3) · Claudio Anasetti, MD (3) · Claudio G. Brunstein, MD, PhD (3) · David G. Savage, MD (3) · Elias Jabbour (3) · Francis Giles (3) · Paul Martin (3) · Philip L. McCarthy, MD (3)
PMID 32499241, PMID 21715313, PMID 35007144, PMID 12114413, PMID 15107815, PMID 15459300, PMID 15466923, PMID 15570084, PMID 16278404, PMID 16775234, PMID 17397698, PMID 17562873, PMID 17640728, PMID 17910637, PMID 17971589, PMID 18327587, PMID 18571721, PMID 18698002, PMID 18769450, PMID 18838477, PMID 18989154, PMID 18997171, PMID 19139736, PMID 19179301, PMID 19270260, PMID 19286996, PMID 19706886, PMID 19841031, PMID 1994541, PMID 20124511, PMID 20460644, PMID 20466853, PMID 20511167, PMID 20858843, PMID 20860038, PMID 20952518, PMID 21403127, PMID 21508120, PMID 21523798, PMID 21719601, PMID 21791475, PMID 22002488, PMID 22009536, PMID 22157574, PMID 22430088, PMID 22480131, PMID 23358983, PMID 23393050, PMID 23443507, PMID 24362550
P30CA043703 (12), P30CA015704 (10), P30CA006973 (9), P30CA033572 (9), P30CA016672 (8), P30CA068485 (7), U01CA062461 (7), P01CA018029 (6), P30CA022453 (5), P30CA072720 (5), U01CA097452 (5), P30CA016086 (4), 2023 (3), N01CM62202 (3), P01CA015396 (3)